Taesoo Kim

Taesoo Kim

Auto-generated profile, based on publicly available information

Taesoo Kim

Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
ISInsa M. Schmidt
Insa M. Schmidt
ASAditya L. Surapaneni
Aditya L. Surapaneni
RZRunqi Zhao
Runqi Zhao
DUDhairya Upadhyay
Dhairya Upadhyay
WYWan-Jin Yeo
Wan-Jin Yeo
SWSushrut S. Waikar
Sushrut S. Waikar
The kidney tubules constitute two-thirds of the cells of the kidney and account for the majority of the organ’s metabolic energy expenditure. Acute tubular injury (ATI) is observed across various types of kidney diseases and may significantly contribute to progression to kidney failure. Non-invasive biomarkers of ATI may allow for early detection and drug development. Using the SomaScan proteomics platform on 434 patients with biopsy-confirmed kidney disease, we here identify plasma biomarkers associated with ATI severity. We employ regional transcriptomics and proteomics, single-cell RNA sequencing, and pathway analysis to explore biomarker protein and gene expression and enriched biological pathways. Additionally, we examine ATI biomarker associations with acute kidney injury (AKI) in the Kidney Precision Medicine Project (KPMP) (n = 44), the Atherosclerosis Risk in Communities (ARIC) study (n = 4610), and the COVID-19 Host Response and Clinical Outcomes (CHROME) study (n = 268). Our findings indicate 156 plasma proteins significantly linked to ATI with osteopontin, macrophage mannose receptor 1, and tenascin C showing the strongest associations. Pathway analysis highlight immune regulation and organelle stress responses in ATI pathogenesis.

24 April 2024 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
TKTaesoo Kim
Taesoo Kim
ASAditya L. Surapaneni
Aditya L. Surapaneni
ISInsa M. Schmidt
Insa M. Schmidt
MEMichael Eadon
Michael Eadon
SKSahir Kalim
Sahir Kalim
EREugene P. Rhee
Eugene P. Rhee
Key Points: Proteomic profiling identified 35 blood proteins associated with chronic histopathologic lesions in the kidney. Testican-2 was expressed in the glomerulus, released by the kidney into circulation, and inversely associated with glomerulosclerosis severity. NELL1 was expressed in tubular epithelial cells, released by the kidney into circulation, and inversely associated with interstitial fibrosis and tubular atrophy severity. Background: The severity of chronic histopathologic lesions on kidney biopsy is independently associated with higher risk of progressive CKD. Because kidney biopsies are invasive, identification of blood markers that report on underlying kidney histopathology has the potential to enhance CKD care. Methods: We examined the association between 6592 plasma protein levels measured by aptamers and the severity of interstitial fibrosis and tubular atrophy (IFTA), glomerulosclerosis, arteriolar sclerosis, and arterial sclerosis among 434 participants of the Boston Kidney Biopsy Cohort. For proteins significantly associated with at least one histologic lesion, we assessed renal arteriovenous protein gradients among 21 individuals who had undergone invasive catheterization and assessed the expression of the cognate gene among 47 individuals with single-cell RNA sequencing data in the Kidney Precision Medicine Project. Results: In models adjusted for eGFR, proteinuria, and demographic factors, we identified 35 proteins associated with one or more chronic histologic lesions, including 20 specific for IFTA, eight specific for glomerulosclerosis, and one specific for arteriolar sclerosis. In general, higher levels of these proteins were associated with more severe histologic score and lower eGFR. Exceptions included testican-2 and NELL1, which were associated with less glomerulosclerosis and IFTA, respectively, and higher eGFR; notably, both of these proteins demonstrated significantly higher levels from artery to renal vein, demonstrating net kidney release. In the Kidney Precision Medicine Project, 13 of the 35 protein hits had cognate gene expression enriched in one or more cell types in the kidney, including podocyte expression of select glomerulosclerosis markers (including testican-2) and tubular expression of several IFTA markers (including NELL1). Conclusions: Proteomic analysis identified circulating proteins associated with chronic histopathologic lesions, some of which had concordant site-specific expression within the kidney.

21 January 2025 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
TKTaesoo Kim
Taesoo Kim
ASAditya L. Surapaneni
Aditya L. Surapaneni
HLHubert Leo
Hubert Leo
NFNora F. Fino
Nora F. Fino
LILesley A. Inker
Lesley A. Inker
EREugene P. Rhee
Eugene P. Rhee

16 October 2024 in Kidney Medicine
Verified
Journal Article
Open access
TKTaesoo Kim
Taesoo Kim
DHDirk M. Hentschel
Dirk M. Hentschel
DMDavid B. Mount
David B. Mount
KRKatherine Scovner Ravi
Katherine Scovner Ravi

28 October 2025 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
DWDonghai Wen
Donghai Wen
QZQian Zhang
Qian Zhang
JAJohannes van Agthoven
Johannes van Agthoven
AWAstrid Weins
Astrid Weins
IRIvy A. Rosales
Ivy A. Rosales
EREugene P. Rhee
Eugene P. Rhee
Key Points: Testican-2 reduced adriamycin-induced podocyte injury in vitro and in vivo . Testican-2 interacted with vitronectin and reduced vitronectin-mediated integrin α V β 3 activation in vitro . Exogenous testican-2 circulated to the kidney, bound vitronectin, and conferred podocyte protection, even when endogenous testican-2 was absent. Background: Testican-2 is a podocyte-derived glycoprotein encoded by SPOCK2 . Circulating levels of testican-2 are associated with less glomerulosclerosis and better kidney prognosis, but its biologic function in the podocyte is unknown. Methods: We studied the protective effect of testican-2 on immortalized cultured human podocytes and in mice treated with adriamycin. We used immunoprecipitation mass spectrometry to identify binding partners of testican-2 and biolayer interferometry to characterize these protein–protein interactions. Using global and podocyte-specific Spock2 knockout mice, we assessed the effect of testican-2 deficiency in models of podocyte injury and also tested whether exogenous testican-2 confers podocyte protection in testican-2–deficient mice. Finally, we analyzed testican-2 expression in human kidney biopsy samples. Results: Testican-2 reduced adriamycin-induced podocyte injury in cultured human podocytes and mice. Vitronectin was a strong binding partner for testican-2, and testican-2 inhibited the interaction between vitronectin and integrin α V β 3, an effector of podocyte injury. Consistent with this, testican-2 administration reduced activation of integrin β 3 in injured podocytes. Furthermore, Spock2 deficiency increased susceptibility to podocyte injury due to adriamycin- and streptozotocin-induced diabetes, as determined by albuminuria, foot process effacement, nephrin expression, and Wilms' tumor 1-positive podocyte number. Importantly, exogenous testican-2 circulated to the kidney, bound to vitronectin, reduced vitronectin-integrin β 3 interaction, and reduced podocyte injury in Spock2 -deficient mice. Finally, glomerular testican-2 expression was reduced in human focal segmental glomerulosclerosis and diabetic kidney disease, but not tubulointerstitial nephropathy. Conclusions: Testican-2 modulated the podocyte's interaction with its extracellular matrix and had a functional role in kidney protection.

1 January 2022 in The American Journal of Medicine
Verified
Journal Article
Closed access
CRChristine Rutlen
Christine Rutlen
PBPhilip Blatt
Philip Blatt
TKTaesoo Kim
Taesoo Kim
JBJoel Burnett
Joel Burnett